Answers are grounded in this paper and cite their sources.
Preclinical drug screening for non-small cell lung cancer (NSCLC) is limited by the inadequate recapitulation of the tumor microenvironment in conventional two-dimensional (2D) culture systems. Here, using PC-9 cells as a proof of concept, we constructed a three-dimensional (3D) cell culture platform based on self-assembling peptides (SAPs) Sciobio-II and evaluated its utility for NSCLC drug sensitivity testing. Structural and mechanical characterization indicates that Sciobio-II self-assembles upon ionic triggering into an ordered, highly interconnected nanofibrous scaffold with long-term stability and hydrogel mechanics. PC-9 cells spontaneously formed spheroids of 50–150 μm in diameter within this 3D system and maintained high proliferative activity for at least 14 days. Drug sensitivity testing to 17 antitumor drugs demonstrated that the 3D culture system exhibits a clear dose-dependent response while yielding quantifiable and comparable values of the area under the curve (AUC), thereby mitigating the evaluation bias associated with the absence of an extracellular matrix (ECM) barrier in 2D culture. This proof-of-concept platform provides a promising in vitro tool that reconstructs tumor ECM structural features for preclinical drug screening and candidate prioritization in NSCLC.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: